Decnupaz Injection, Powder, Lyophilized, For Solution
NDC Package 0074-0282-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Decnupaz (pivekimab sunirine-pvzy) injection is dECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-0282 and is authorized under FDA application BLA761460.

Identification & Billing

NDC Package Code
0074-0282-02
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 1.15 mL in 1 VIAL, SINGLE-DOSE
Product Code
0074-0282
11-Digit Billing Format
00074028202
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Decnupaz
Non-Proprietary Name
Pivekimab Sunirine-pvzy
Substance Name
Pivekimab Sunirine
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
PIVEKIMAB SUNIRINE 2 mg/mL
Usage Information
DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761460
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
05-27-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-0282-02 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 1.15 ml in 1 vial, single-dose of Decnupaz, a human prescription drug labeled by Abbvie Inc.. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains pivekimab sunirine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on May 27, 2026. The current certification is valid through December 31, 2027.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074028202. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-0282-02
11-Digit CMS (5-4-2)
00074-0282-02

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.